Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Marc Phelip

Showing results (81-90 of 118) with videos related to

Pageof 12
Sort By:
Oncotarget|June 2, 2018
Outcomes prediction in pre-operative radiotherapy locally advanced rectal cancer: leucocyte assessment as immune biomarkerAlexis Vallard, Max-Adrien Garcia, Peng Diao, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2014
Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised studyJean-Marc Phelip, Véronique Vendrely, Florian Rostain, et al.
Therapeutic Advances in Gastroenterology|October 11, 2019
Folfirinox <i>versus</i> gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score studyNicolas Williet, Angélique Saint, Anne-Laure Pointet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2018
Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)Thomas Aparicio, Francois Ghiringhelli, Valérie Boige, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2021
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 TrialLaetitia Dahan, Nicolas Williet, Karine Le Malicot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2021
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II StudyJean Marc Phelip, Jérôme Desrame, Julien Edeline, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2022
Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studiesJulien Edeline, Satoshi Hirano, Aurélie Bertaut, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 21, 2023
Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trialPhilippe Merle, Jean-Frédéric Blanc, Julien Edeline, et al.
Frontiers in Oncology|October 11, 2021
Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case ReportRomain Varnier, Thibaut Garrivier, Emilie Hafliger, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2022
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD studyCôme Lepage, Jean-Marc Phelip, Astrid Lievre, et al.
Pageof 12

Showing results (81-90 of 118) with videos related to

Sort By:
Pageof 12
Oncotarget|June 2, 2018
Outcomes prediction in pre-operative radiotherapy locally advanced rectal cancer: leucocyte assessment as immune biomarkerAlexis Vallard, Max-Adrien Garcia, Peng Diao, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2014
Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised studyJean-Marc Phelip, Véronique Vendrely, Florian Rostain, et al.
Therapeutic Advances in Gastroenterology|October 11, 2019
Folfirinox <i>versus</i> gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score studyNicolas Williet, Angélique Saint, Anne-Laure Pointet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2018
Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)Thomas Aparicio, Francois Ghiringhelli, Valérie Boige, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2021
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 TrialLaetitia Dahan, Nicolas Williet, Karine Le Malicot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2021
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II StudyJean Marc Phelip, Jérôme Desrame, Julien Edeline, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2022
Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studiesJulien Edeline, Satoshi Hirano, Aurélie Bertaut, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 21, 2023
Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trialPhilippe Merle, Jean-Frédéric Blanc, Julien Edeline, et al.
Frontiers in Oncology|October 11, 2021
Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case ReportRomain Varnier, Thibaut Garrivier, Emilie Hafliger, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2022
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD studyCôme Lepage, Jean-Marc Phelip, Astrid Lievre, et al.
Pageof 12